Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

Description:
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Relapsed chronic lymphocytic leukemia (CLL) is a type of cancer chronic lymphocytic leukemia, that the cancer has come back after remission was achieved with treatment. Symptoms include weakness, feeling tired, weight loss, fever, night sweats and enlarged lymph nodes, pain or a sense of fullness in the belly which is caused by an enlarged spleen.

Report Highlights:
Pharmaceutical and Healthcare latest pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 21, 20 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Relapsed Chronic Lymphocytic Leukemia (CLL).

Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic
Leukemia (CLL) (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction

Relapsed Chronic Lymphocytic Leukemia (CLL) Overview

Therapeutics Development

Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview

Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis

Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies

Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies

Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes

Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development

4SC AG

AAbbVie Inc

Aptevo Therapeutics Inc

Astellas Pharma Inc.

Astex Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
(dezapelisib + itacitinib adipate) - Drug Profile
4SC-202 - Drug Profile
acalabrutinib - Drug Profile
ACP-319 - Drug Profile
afuresertib hydrochloride - Drug Profile
AGS-67E - Drug Profile
AT-7519 - Drug Profile
atezolizumab - Drug Profile
BI-836826 - Drug Profile
BMS-986016 - Drug Profile
buparlisib hydrochloride - Drug Profile
CBM-C19.1 - Drug Profile
CC-122 - Drug Profile
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile
Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile
duvelisib - Drug Profile
HMPL-523 - Drug Profile
idelalisib - Drug Profile
IMGN-529 - Drug Profile
IMMU-114 - Drug Profile
JCAR-014 - Drug Profile
JCAR-015 - Drug Profile
lirilumab - Drug Profile
monalizumab - Drug Profile
MOR-208 - Drug Profile
nivolumab - Drug Profile
obinutuzumab - Drug Profile
ofatumumab - Drug Profile
otlertuzumab - Drug Profile
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2016

Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3961156/](http://www.researchandmarkets.com/reports/3961156/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016
Web Address: http://www.researchandmarkets.com/reports/3961156/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>□</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>□</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof

First Name: ___________________________  Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World